Co-Diagnostics, Inc.
CODX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -10.8% | 224% | -66.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 81.9% | 80.3% | 57.1% | -70.8% |
| R&D Expenses | $4 | $5 | $5 | $5 |
| G&A Expenses | $2 | $3 | $3 | $6 |
| SG&A Expenses | $2 | $3 | $3 | $7 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $8 | $9 | $12 |
| Operating Income | -$7 | -$8 | -$9 | -$12 |
| % Margin | -4,824.5% | -4,946.1% | -17,009.7% | -7,973.9% |
| Other Income/Exp. Net | -$0 | $0 | $1 | $1 |
| Pre-Tax Income | -$7 | -$8 | -$8 | -$11 |
| Tax Expense | -$1 | $0 | $0 | -$0 |
| Net Income | -$6 | -$8 | -$8 | -$11 |
| % Margin | -4,049.3% | -4,745% | -14,983.5% | -7,387.4% |
| EPS | -0.16 | -0.23 | -0.24 | -0.33 |
| % Growth | 30.4% | 4.2% | 27.3% | – |
| EPS Diluted | -0.16 | -0.23 | -0.24 | -0.33 |
| Weighted Avg Shares Out | 38 | 33 | 32 | 33 |
| Weighted Avg Shares Out Dil | 38 | 33 | 32 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$8 | -$8 | -$12 |
| % Margin | -4,640.6% | -4,767.3% | -16,451.9% | -7,734.7% |